SCHEMBL210601

SCHEMBL210601

NCCC[C@H](NC(=O)OCc1ccccc1)C(=O)O

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 5/20 0.64
ITGA2B P08514 4/20 0.64
PRSS1 P07477 1/20 0.61
PRSS2 P07478 1/20 0.61
PRSS3 P35030 1/20 0.61
TPSAB1 Q15661 1/20 0.61
ECE1 P42892 1/20 0.61
CPB1 P15086 1/20 0.58
CPB2 Q96IY4 1/20 0.58
FOLH1 Q04609 2/20 0.57
SIRT2 Q8IXJ6 3/20 0.56
SIRT1 Q96EB6 3/20 0.56
CTSL P07711 2/20 0.55
CTSS P25774 1/20 0.55
ACE P12821 1/20 0.55
ITGAV P06756 1/20 0.53
SIRT3 Q9NTG7 2/20 0.53
DPP4 P27487 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL210602 1.00 ITGB3 (0.64) ITGB3ITGA2BPRSS1PRSS2PRSS3
SCHEMBL2367228 1.00 ITGB3 (0.64) ITGB3ITGA2BPRSS1PRSS2PRSS3
Hydrochloric Acid SCHEMBL2500832 0.99 ITGB3 (0.63) ITGB3ITGA2BPRSS1PRSS2PRSS3
SCHEMBL287474 0.96 ITGB3 (0.66) ITGB3ITGA2BPRSS1PRSS2PRSS3
SCHEMBL6476819 0.96 ITGB3 (0.66) ITGB3ITGA2BPRSS1PRSS2PRSS3
SCHEMBL287475 0.96 ITGB3 (0.66) ITGB3ITGA2BPRSS1PRSS2PRSS3
SCHEMBL15968143 0.96 ITGB3 (0.66) ITGB3ITGA2BPRSS1PRSS2PRSS3
SCHEMBL24188458 0.95 ECE1 (0.62) ITGB3ITGA2BPRSS1PRSS2PRSS3
Hydrochloric Acid SCHEMBL4994643 0.95 ITGB3 (0.65) ITGB3ITGA2BPRSS1PRSS2PRSS3
Hydrochloric Acid SCHEMBL21219335 0.95 ITGB3 (0.65) ITGB3ITGA2BPRSS1PRSS2PRSS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748609-B2 Catalysis of diketopiperazine synthesis MANNKIND CORPORATION (US) 2014-06-10 US claimed
US-20120178935-A1 Catalysis of Diketopiperazine Synthesis MANNKIND CORPORATION (US) 2012-07-12 US claimed
US-8202992-B2 Catalysis of diketopiperazine synthesis MANNKIND CORPORATION (US) 2012-06-19 US claimed
US-20100087642-A1 Catalysis of Diketopiperazine Synthesis MANNKIND CORPORATION (US) 2010-04-08 US claimed
EP-1088020-B1 FUNCTIONALISED POLYMERS OF ALPHA-AMINO ACIDS AND THE METHOD OF PREPARATION THEREOF USTAV MAKROMOLEKULARNI CHEMIE (CZ) 2002-12-18 EP claimed
EP-1088020-A1 FUNCTIONALISED POLYMERS OF ALPHA-AMINO ACIDS AND THE METHOD OF PREPARATION THEREOF USTAV MAKROMOLEKULARNI CHEMIE AKADEMIE VED CESKE REPUBLIKY (CZ) 2001-04-04 EP claimed
WO-1999064495-A1 FUNCTIONALISED POLYMERS OF α-AMINO ACIDS AND THE METHOD OF PREPARATION THEREOF ÚSTAV MAKROMOLEKULÁRNÍ CHEMIE AKADEMIE VĚD ČESKÉ REPUBLIKY (CZ) 1999-12-16 WO claimed
US-3936469-A Process for preparing N-carboxylic anhydrides of amino acids KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JA) 1976-02-03 US claimed
US-20260042739-A1 Formation of N-Protected 3,6-bis-(4-aminoalkyl)-2,5,diketopiperazine MANNKIND CORP (US) 2026-02-12 US disclosed
US-12465582-B2 (S)-2-amino-6-((3-aminopropyl)amino)hexanoic acid (APL) for use in the treatment of non-alcoholic steatohepatitis (NASH), liver inflammation, hepatocellular ballooning, liver fibrosis and steatosis Temple University—Of the Commonwealth System of Higher Education (US) 2025-11-11 US disclosed
US-12459903-B2 Formation of n-protected 3,6-bis-(4-aminoalkyl)-2,5,diketopiperazine MANNKIND CORPORATION (US) 2025-11-04 US disclosed
EP-4595969-A2 COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE Temple University Of The Commonwealth System Of Higher Education (US) 2025-08-06 EP disclosed
US-20250241943-A1 BI-FUNCTIONAL CO-POLYMER USE FOR OPHTHALMIC AND OTHER TOPICAL AND LOCAL APPLICATIONS CALM WATER THERAPEUTICS LLC 2025-07-31 US disclosed
WO-2025151642-A1 MODIFIED ELONGATION FACTOR P AND METHODS OF USE THEREOF ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2025-07-17 WO disclosed
EP-0230037-A1 Cytoprotective derivatives useful in ischemic diseases, their preparation and compositions containing them ITALFARMACO S.p.A. (IT) 1987-07-29 EP disclosed
US-4616012-A BENZOTHIADIZINYL AND QUINAZOLINYL DERIVATIVES SCHERING CORPORATION (US) 1986-10-07 US disclosed
EP-0178911-A2 Composition containing a penem or carbapenem antibiotic SANKYO COMPANY LIMITED (JP) 1986-04-23 EP disclosed
EP-0157572-A2 Acyltripeptide immunostimulants PFIZER INC. (US) 1985-10-09 EP disclosed
EP-0017309-A1 Cyclic hexapeptide and dipeptide and compositions containing them MERCK & CO. INC. (US) 1980-10-15 EP disclosed
US-3936469-A Process for preparing N-carboxylic anhydrides of amino acids KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JA) 1976-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260042739-A1 Formation of N-Protected 3,6-bis-(4-aminoalkyl)-2,5,diketopiperazine ACMSD, DNPEP, PGM2 ITGB3 4201/4885ITGA2B 4448/4885PRSS1 1750/4885
US-20100087642-A1 Catalysis of Diketopiperazine Synthesis PHYKPL, DNPEP, NPEPPS ITGB3 4092/4885ITGA2B 4360/4885PRSS1 807/4885
US-12459903-B2 Formation of n-protected 3,6-bis-(4-aminoalkyl)-2,5,diketopiperazine PGM2, DNPEP, NPEPPS ITGB3 4215/4885ITGA2B 4688/4885PRSS1 1809/4885
US-20120178935-A1 Catalysis of Diketopiperazine Synthesis PHYKPL, DNPEP, NPEPPS ITGB3 4092/4885ITGA2B 4360/4885PRSS1 807/4885
US-12465582-B2 (S)-2-amino-6-((3-aminopropyl)amino)hexanoic acid (APL) for use in the treatment of non-alcoholic steatohepatitis (NASH), liver inflammation, hepatocellular ballooning, liver fibrosis and steatosis FABP1, AADAT, FABP6 ITGB3 2210/4885ITGA2B 1846/4885PRSS1 334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.